A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 for 12 Weeks in the Treatment of Moderate-to-Severe Acne Vulgaris (Study FX2017-22)

Trial Profile

A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 for 12 Weeks in the Treatment of Moderate-to-Severe Acne Vulgaris (Study FX2017-22)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Jul 2018

At a glance

  • Drugs Minocycline (Primary)
  • Indications Acne vulgaris
  • Focus Registrational; Therapeutic Use
  • Sponsors Foamix
  • Most Recent Events

    • 08 May 2018 According to a Foamix media release, NDA filing for FMX101 is planned for the end of 2018.
    • 07 May 2018 According to a Foamix media release, final patient has been enrolled and dosed in this study. Results are expected in the third quarter of 2018.
    • 07 May 2018 Status changed from recruiting to active, no longer recruiting, according to the Foamix media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top